Copyright
©The Author(s) 2022.
World J Clin Oncol. Apr 24, 2022; 13(4): 287-302
Published online Apr 24, 2022. doi: 10.5306/wjco.v13.i4.287
Published online Apr 24, 2022. doi: 10.5306/wjco.v13.i4.287
Disease-free survival 5 yr of follow-up[6] | Disease-free survival 15 yr of follow-up, present study | Overall survival 15 yr of follow-up, present study | ||||||
Variable | HR (95%CI) | R2N | HR (95%CI) | R2N | R2D | HR (95%CI) | R2N | R2D |
PET axillary/sternal (positive vs negative) | 2.81 (1.17, 6.74) | 0.059 | 1.74 (0.96, 3.14) | 0.030 | 0.053 | 3.08 (1.42, 6.69) | 0.077 | 0.159 |
Age at diagnosis (yr) | 1.05 (1.01, 1.09) | 0.046 | 1.03 (1.00, 1.06) | 0.047 | 0.075 | 1.06 (1.02, 1.10) | 0.109 | 0.227 |
Adjuvant hormone therapy (yes vs no) | 0.43 (0.16, 1.13) | 0.030 | 0.51 (0.24, 1.08) | 0.025 | 0.049 | 0.46 (0.18, 1.18) | 0.020 | 0.083 |
Full model | NA | 0.091 | 0.142 | 0.189 | 0.396 |
- Citation: Perrin J, Farid K, Van Parijs H, Gorobets O, Vinh-Hung V, Nguyen NP, Djassemi N, De Ridder M, Everaert H. Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis. World J Clin Oncol 2022; 13(4): 287-302
- URL: https://www.wjgnet.com/2218-4333/full/v13/i4/287.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i4.287